Exozymes appoints experienced biomanufacturing executive, damien perriman, as cco

Expanded leadership team as exozymes ramps up commercial growth damien perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners monrovia, ca, april 02, 2025 (globe newswire) -- today, exozymes inc. (nasdaq: exoz) (“exozymes”) - a pioneer of ai-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of damien perriman to a newly created role as chief commercial officer (cco). perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals.
CCO Ratings Summary
CCO Quant Ranking